Survivin peptide-major histocompatibility complex class I complex

The **Survivin peptide-major histocompatibility complex class I complex** is formed when short antigenic peptides derived from the tumor-associated protein survivin are bound by MHC class I molecules on the surface of antigen-presenting cells or tumor cells[2][3]. Survivin is an inhibitor of apoptosis family protein strongly associated with cancer cell survival, proliferation, and resistance to therapy, but its expression in normal adult tissues is limited[2]. Specific survivin-derived peptides can be presented by MHC class I molecules (such as HLA-A*0201), whereupon they are recognized by cytotoxic T lymphocytes; this recognition underlies their use as cancer immunotherapy targets and vaccines[3]. The survivin peptide-MHC I complex serves as a tumor-specific antigenic epitope, enabling immune targeting of survivin-expressing cancer cells. Targeting this complex seeks to induce a strong and specific anti-tumor CD8+ T cell response, offering therapeutic potential with careful patient and peptide selection[2][3].

Other names

Survivin peptide–MHC I complexSurvivin epitope–MHC class I complex

Generation of cytotoxic T lymphocyte response via MHC I-restricted antigen presentation Immune-mediated killing of survivin-expressing tumor cells